The HeartMate 3 (HM3; [Full MagLev, Abbott Laboratories, Chicago, Illinois]) was recently approved as a destination therapy; this VAD has a number of unique advantages that allow for its off-label use for biventricular support. Here, we describe the use of two HM3s as a TAH in a patient as a bridge to transplant.

A novel biventricular assist device (BiVAD) setup can provide a durable bridge to orthotopic heart transplant (OHT) in selected cases. Case: A 57 year old male with atrial fibrillation and alcohol associated cardiomyopathy (ejection fraction 10%) progressed to severe INTERMACS-1 cardiogenic shock (CS) with biventricular (BiV) dysfunction.

Heart transplantation remains the gold standard therapy for patients with end-stage heart failure, but it is greatly limited by the number of available donor organs. 1 A ventricular assist device (VAD) can be an alternative or a bridge to transplantation in select patients. 2 In a subset of patients, heart failure is biventricular and left VAD (...

The HeartMate 3 (HM3, Full MagLev™) was recently approved as a destination therapy; this VAD has a number of unique advantages that allow for its off-label use for biventricular support. Here we describe the use of 2 HM3s as a total artificial heart in a patient as a bridge to transplant.

One emerging strategy is the use of 2 fully magnetically levitated durable ventricu-lar assist devices (HeartMate 3s) in a biventricular configuration. The use of a HeartMate 3 as a right ventricular assist device (RVAD) requires several complex technical modifica-tions.

Despite one week of veno-arterial extracorporeal membrane oxygenation (VA-ECMO), her cardiac function did not improve, necessitating the successful implantation of a durable biventricular assist device (BiVAD). Seven days following re-transplantation, the patient underwent implantation of two HeartMate 3 (HM3) VADs as total heart replacement.

a durable biventricular assist device (BiVAD). Case Video Summary: Seven days following re-transplantation, the patient underwent implantation of two HeartMate 3 (HM3) VADs as total heart replacement. The myocardium was necrotic, necessitating a biventriculectomy after establishing cardiopulmonary bypass.

2023年8月31日 · Urganci et al. have shared their approach of the ‘HeartMate 6’ where 2 HM3 devices were implanted in a virgin chest of a patient with Yamaguchi syndrome. Their technique involved complete biventriculectomies and excision of atrioventricular valves.

2020年3月1日 · The Berlin group describes a patient who presents with biventricular failure due to ischaemic cardiomyopathy and ultimately is taken for HM3 LVAD implantation and the advantage of the ‘HeartMate 6’ approach is that HM3 devices are widely available, relatively small and noiseless. Expand

2023年1月6日 · The use of a HeartMate 3 as a right ventricular assist device (RVAD) requires several complex technical modifications. Here, we provide step-wise detailed figures and a comprehensive description of bilateral HeartMate 3 insertion, with a particular focus on right atrial inflow cannulation for the RVAD.